2.High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer.
Zheng LIU ; Jun-Yu ZHANG ; Yun-Jie YANG ; Kun CHANG ; Qi-Feng WANG ; Yun-Yi KONG ; Bo DAI
Asian Journal of Andrology 2022;24(2):147-153
Individualized treatment of prostate cancer depends on an accurate stratification of patients who are sensitive to various treatments. Interleukin-23 (IL-23) was reported to play a significant role in prostate cancer. Here, we aimed to explore the clinical value of IL-23-secreting (IL-23+) cells in prostate cancer patients. We evaluated interleukin-23A (IL-23A) expression in The Cancer Genome Atlas database and retrospectively enrolled 179 treatment-naïve metastatic prostate cancer patients diagnosed in our institute between June 2012 and December 2014. IL-23+ cells were stained and evaluated via immunohistochemistry. Further, survival and multivariate Cox regression analyses were conducted to explore the prognostic value of IL-23+ cells. We found that IL-23A expression correlated with disease progression, while IL-23+ cells were clearly stained within prostate cancer tissue. Patients with higher Gleason scores and multiple metastatic lesions tended to have more IL-23+ cell infiltration. Further analyses showed that patients with higher levels of IL-23+ cells had significantly worse overall survival (hazard ratio [HR] = 2.996, 95% confidence interval [95% CI]: 1.812-4.955; P = 0.001) and a higher risk of developing castration resistance (HR = 2.725, 95% CI: 1.865-3.981; P = 0.001). Moreover, subgroup analyses showed that when patients progressed to a castration-resistant status, the prognostic value of IL-23+ cells was observed only in patients treated with abiraterone instead of docetaxel. Therefore, we showed that high IL-23+ cell infiltration is an independent prognosticator in patients with metastatic prostate cancer. IL-23+ cell infiltration may correlate with abiraterone effectiveness in castration-resistant prostate cancer patients.
Abiraterone Acetate/therapeutic use*
;
Androstenes
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
;
Disease-Free Survival
;
Humans
;
Interleukin-23/metabolism*
;
Male
;
Prostatic Neoplasms, Castration-Resistant/pathology*
;
Retrospective Studies
;
Treatment Outcome
3.Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer.
Yu-Chao NI ; Jin-Ge ZHAO ; Meng-Ni ZHANG ; Yi-Jun ZHANG ; Zhen-Yu YANG ; Ni CHEN ; Jun-Ru CHEN ; Peng-Fei SHEN ; Guang-Xi SUN ; Xing-Ming ZHANG ; Yong-Hong LI ; Hao ZENG
Asian Journal of Andrology 2022;24(2):154-160
Corticosteroid switching can reverse abiraterone resistance in some patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we investigated the potential biomarkers for predicting the efficacy of corticosteroid switching during treatment with abiraterone acetate (AA). We retrospectively analyzed 101 mCRPC patients receiving corticosteroid switching from West China Hospital and Sun Yat-Sen University Cancer Center between January 2016 and December 2018. All cases received AA plus prednisone as first-line therapy during mCRPC. Primary end points were biochemical progression-free survival (bPFS) and overall survival (OS). The risk groups were defined based on multivariate analysis. A total of 42 (41.6%) and 25 (24.8%) patients achieved 30% and 50% decline in prostate-specific antigen (PSA), respectively, after corticosteroid switching. The median bPFS and median OS on AA plus dexamethasone were 4.9 (95% confidence interval [CI]: 3.7-6.0) months and 18.8 (95% CI: 16.2-30.2) months, respectively. Aldo-keto reductase family 1 member C3 (AKR1C3) expression (hazard ratio [HR]: 2.15, 95% Cl: 1.22-3.80, P = 0.008) and baseline serum alkaline phosphatase (ALP; HR: 4.95, 95% Cl: 2.40-10.19, P < 0.001) were independent predictors of efficacy before corticosteroid switching in the multivariate analysis of bPFS. Only baseline serum ALP >160 IU l-1 (HR: 3.41, 95% Cl: 1.57-7.38, P = 0.002) together with PSA level at switch ≥50 ng ml-1 (HR: 2.59, 95% Cl: 1.22-5.47, P = 0.013) independently predicted poorer OS. Based on the predictive factors in multivariate analysis, we developed two risk stratification tools to select candidates for corticosteroid switching. Detection of serum ALP level, PSA level, and tissue AKR1C3 expression in mCRPC patients could help make clinical decisions for corticosteroid switching.
Abiraterone Acetate/therapeutic use*
;
Adrenal Cortex Hormones/therapeutic use*
;
Androstenes
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
;
Dexamethasone/therapeutic use*
;
Disease-Free Survival
;
Humans
;
Male
;
Prednisone/therapeutic use*
;
Prostate-Specific Antigen
;
Prostatic Neoplasms, Castration-Resistant/pathology*
;
Retrospective Studies
;
Treatment Outcome
4.A case of metastatic castration-resistant prostate cancer by abiraterone treatment.
Liuxun LI ; Zhi LONG ; Leye HE
Journal of Central South University(Medical Sciences) 2015;40(6):688-692
We reviewed and analyzed the clinical data for a patient with metastatic castration-resistant prostate cancer (mCRPC) from September, 2009 to December, 2014. After the treatment with abiraterone, patient's performance status improved, pain relieved, total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) markedly decreased. tPSA or fPSA fluctuated between
30 and 50 ng/mL or between 10 and 20 ng/mL. MRI showed the left peripheral zone reduced. MRI and bone single photon emission computed tomography (SPECT) scan showed no new metastasis. These results indicated that application of abiraterone for patient with mCRPC not only decreased prostate specific antigen (PSA) levels and tumor volume, but also blocked bone metastasis progression and enhanced pain relief.
Androstenes
;
therapeutic use
;
Bone Neoplasms
;
drug therapy
;
secondary
;
Disease Progression
;
Humans
;
Male
;
Prostate-Specific Antigen
;
blood
;
Prostatic Neoplasms, Castration-Resistant
;
drug therapy
;
pathology
5.Comparison among measures to prevent intrauterine adhesions after artificial abortion.
Lei LI ; Manman NAI ; Guixiang GAO ; Luwen WANG
Journal of Central South University(Medical Sciences) 2016;41(9):975-978
OBJECTIVE:
To investigate the clinical efficacy of oral medicine and sodium hyaluronate in prevention of intrauterine adhesions after artificial abortion.
METHODS:
A total of 572 patients with early pregnancy termination through artificial abortion, who experienced two or more times of abortion, were retrospectively analyzed. Patients were randomly and voluntarily divided into 4 groups: an artificial cycle group, a drospirenone and ethinylestradiol tablets group, a sodium hyaluronate group, and a control group. The thickness of the endometrium, return time of menses, and the status of intrauterine adhesions were observed.
RESULTS:
The thickness of the endometrium in the artificial period group was greater than that in the control group (P<0.001). It was less in the drospirenone and ethinylestradiol tablets group comparing with that in the control group (P<0.001). There was no significant difference in the thickness of the endometrium between the sodium hyaluronate group and the control group (P=0.717). Return time of menses in the artificial menstrual cycle group and the drospirenone and ethinylestradiol tablets group was shorter than that in the control group (P<0.001). There was no significant difference in return time of menses between the sodium hyaluronate group and the control group (P=0.813). The incidence of intrauterine adhesions could be reduced by the 3 preventive measures (All P<0.01).
CONCLUSION
Drugs for artificial cycle and drospirenone and ethinylestradiol tablets medication immediately after artificial abortion can effectively promote endometrial repair and reduce the incidence of intrauterine adhesions. However, for the patients with poor compliance, drospirenoneand ethinylestradiol tablets are the first choice for prevention of intrauterine adhesion.
Abortion, Induced
;
adverse effects
;
Androstenes
;
pharmacology
;
therapeutic use
;
Endometrium
;
anatomy & histology
;
drug effects
;
Ethinyl Estradiol
;
pharmacology
;
therapeutic use
;
Female
;
Humans
;
Hyaluronic Acid
;
pharmacology
;
therapeutic use
;
Menstrual Cycle
;
drug effects
;
Menstruation
;
drug effects
;
Pregnancy
;
Tissue Adhesions
;
etiology
;
prevention & control
6.Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.
Guo-Wen LIN ; Gao-Xiang LI ; Bo DAI ; Ding-Wei YE ; Yun-Yi KONG ; Yue WANG ; Yi-Jun SHEN
Asian Journal of Andrology 2019;21(2):131-136
This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 146 patients with docetaxel-naïve group (103 cases) and docetaxel-resistant group (43 cases) were enrolled from the Shanghai Cancer Center (Shanghai, China) in this retrospective cohort study. The efficacy endpoints were prostate-specific antigen response rate, prostate-specific antigen progression-free survival, clinical/radiographic progression-free survival, and overall survival in response to abiraterone plus prednisone. Significantly higher prostate-specific antigen response rate was found in docetaxel-naïve group (54.4%, 56/103) compared to docetaxel-resistant group (34.9%, 15/43) (P = 0.047). In addition, significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months, P = 0.005), clinical or radiographic progression-free survival (17.0 vs 12.5 months, P = 0.003), and overall survival (27.0 vs 18.0 months, P = 0.016) were found in docetaxel-naïve group compared to docetaxel-resistant group, respectively. The univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall survival. To sum up, our data suggested that abiraterone plus prednisone was efficient in both docetaxel-naïve and docetaxel-resistant Chinese patients. Moreover, higher PSA response rate and longer overall survival were observed in the docetaxel-naïve group, which suggested that abiraterone was more effective for docetaxel- naïve patients than for docetaxel failures.
Aged
;
Aged, 80 and over
;
Androstenes/therapeutic use*
;
Antineoplastic Agents, Hormonal/therapeutic use*
;
China
;
Disease Progression
;
Disease-Free Survival
;
Drug Therapy, Combination
;
Humans
;
Male
;
Middle Aged
;
Prednisone/therapeutic use*
;
Prostatic Neoplasms, Castration-Resistant/mortality*
;
Retrospective Studies
;
Survival Rate
;
Treatment Outcome